The diversity of angiotensin II (Ang II) actions implies multiple receptor subtypes. To characterize these subtypes in rat mesangial cells, we used the angiotensin subtype LA (ATu) antagonist losartan (DuP 753), the subtype 2/1B (AT 2 /AT, B ) antagonist PD 123319, and the AT 2 antagonist CGP 421L2A in radioreceptor and adenyiyi cyclase assays. In radioligand binding competition experiments, approximately 25% of the specific binding sites labeled by II5 I-[Sar']Ang II were inhibited by low concentrations of PD 123319 (0.1 to 10 nM), whereas the AT 2 antagonist CGP 42112A was inactive at concentrations less than 0.1 fiM. Conversely, losartan inhibited 75% of the binding at low concentrations (0.1 nM to 0.1 fiM), but higher concentrations (up to 10 /iM) were required to inhibit the second component of 
R ecently, two subtypes of angiotensin II (Ang II) receptors have been described based on their differential affinities for the nonpeptide antagonists losartan (DuP 753) compared with PD 123319 or the peptide CGP 42112A. 1 The Ang II binding site antagonized by losartan, termed the ATi subtype, was the predominant receptor subtype found in the vascular smooth muscle, adrenal cortex, liver, and some brain regions. The Ang II binding site antagonized by PD 123319 and CGP 42112A, termed the AT 2 subtype, was the major subtype in uterine smooth muscle, ovary, adrenal medulla, the developing rat fetus, and other brain regions. 2 Most of the known actions of Ang II are mediated by the AT, receptor, such as phosphoinositide hydrolysis, regulation of calcium channels, inhibition of adenyiyi cyclase, and stimulation of phospholipase A 2 . 3~i The AT 2 receptor mediates inhibition of guanylyl cyclase and regulation of potassium channels 6 -8 ; however, the signaling mechanism for the AT 2 receptor remains undefined. Recently, complementary DNA clones for bovine 9 and rat 10 AT, receptors have been isolated and characterized. The cloned AT, receptors have the typical features of G protein-coupled receptors and are linked to phosphoinositide-specific phospholipase C.
Assessments of binding kinetics and signal transduction mechanisms in the kidney suggest that more than one population of high-affinity Ang II receptors exists. 5 We have recently observed a novel pharmacologically distinct Ang II receptor subtype in glomerular mesangial cells that is sensitive to PD 123319 and coupled to G protein. 11 This receptor is distinct from the AT 2 subtype, which is not expressed by mesangial cells. As adenyiyi cyclase is an important G protein-coupled signal transduction system in the kidney, the present studies were designed to determine whether one or both receptor subtypes are linked to it.
Methods

Mesangial Cell Culture and Membrane Preparation
Glomerular isolation and tissue culture of mesangial cells were performed as previously reported. 11 Mesangial cells were cultured in RPMI 1640 with 20% fetal calf serum. Cells were used for studies of Ang II receptor interaction between the third and eighth passages and were harvested at 4°C by gentle scraping and rinsing with calcium-free Hanks' solution and pelleting at 250g for 5 minutes. Mesangial cells were homogenized in 15 mL ice-cold HEPES-Tris buffer, pH 7.4, containing 100 JUM 1,10-phenanthroline, 1 mM phenylmethanesulfonyl fluoride, 5 JAM leupeptin, 7 /xM phosphoramidon, 4 yM pepstatin, 1 mM EDTA, and 250 mM sucrose. Homogenates were centrifuged at l,000g for 5 minutes at 4 C C. The pellets were resuspended in 20 mL homogenization buffer and homogenized and centrifuged at l,000g for 5 minutes. The combined supernatants were centrifuged at 48,000g for 20 minutes at 4°C, and resulting pellets were resuspended in 35 mL of 50 mM Tris-HCl buffer, pH 7.7. After being recentrifuged at 48,000g for 20 minutes, the membranes were used in binding and adenylyl cyclase assays.
Radioreceptor Binding Assay
Binding assays were performed with 125 I-[Sar']Ang II for determination of specific binding to Ang II receptor subtypes as previously described.
11 Membranes (20 to 50 ^g protein) were incubated with 0.1 to 0.5 nM 125 I-[Sar ]Ang II and varying amounts of unlabeled hormone in a total volume of 250 fiL containing 50 mM Tris-HCl (pH 7.7), 120 mM NaCl, 0.5 mM MgCl 2 , 0.5 mg/mL bovine serum albumin, 100 nM bacitracin, 10 £iM phosphoramidon, 50 /xM phenylmethanesulfonyl fluoride, and 10 fig/mL soybean trypsin inhibitor for 60 minutes at 23°C. The incubation was stopped by vacuum filtration through Whatman GF/C filters (presoaked in 0.1% bovine serum albumin) to isolate receptor-bound radioactivity. The filters were washed four times with 5 mL ice-cold Tris-HCl containing NaCl and MgCl 2 and counted at 80% efficiency in a gamma counter. Nonspecific binding was defined in the presence of 2.0 JAM unlabeled Ang II.
Adenylyl Cyclase Assay
Adenylyl cyclase was determined by measuring the formation of cyclic AMP by radioimmunology assay as described previously in this laboratory 12 with some modifications. Briefly, the assay system for the determination of adenylyl cyclase activity contained 25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 4 mM MgCl 2 , 4 mM ATP, 0.01 mM GTP, 2 mM isobutylmethylxanthine, 7.5 mM creatine phosphate, and 15 U/mL creatine phosphokinase. Reaction was initiated by adding 40 fig mesangial cell membrane protein or regeneration system at 26°C for 30 minutes and was stopped by 0.5 mL of 50 mM sodium acetate buffer, pH 6.2. The amount of cyclic AMP formed was determined by radioimmunology assay. 13 
Calculations
Results are expressed as mean±SEM. Data were entered as disintegrations per minute into the EQUILIB-RIUM BINDING DATA ANALYSIS PROGRAM 14 to obtain estimates of half-maximal inhibitory concentration (IQo) and Hill slope and to create input files for the LIGAND program. Subsequently, 4 to 10 experiments were analyzed simultaneously by use of the LJGAND program for nonlinear curve fitting. 15 Dose-response curves were analyzed by nonlinear curve fitting using logistic equations (INPLOT, GRAPHPAD Software, San Diego, Calif.).
Materials
Losartan was donated by Du Pont Merck Pharmaceutical Co., Wilmington, Del. PD 123319 was donated by Parke-Davis, Ann Arbor, Mich., and CGP 42112A by CIBA-GEIGY, Basel, Switzerland. Iodine-125 was purchased from Amersham Corp., Arlington Heights, 111. Other compounds were obtained from Research Biochemicals International, Natick, Mass.; Sigma Chemical Co., St. Louis, Mo.; Peninsula Laboratories, Belmont, Calif.; and Boehringer Mannheim Biochemicals, Indianapolis, Ind.
Results
Binding Studies of Mesangial Cell Membranes
In agreement with our previous studies, ]Ang II were inhibited by low concentrations of PD 123319 (0.1 to 10 nM), whereas the remaining 75% of the sites were not inhibited even by 1,000-fold higher concentrations.
The interaction of losartan and PD 123319 with 12i I-[Sar']Ang II binding could be modeled by nonlinear curve fitting as two distinct populations of sites. The major proportion of sites showed higher affinity for losartan (nanomolar) and lower affinity for PD 123319 (micromolar). Conversely, the minor site displayed a higher affinity (nanomolar) for PD 123319 and lower affinity (micromolar) for losartan. Losartan showed 82-fold higher affinity for the majority site; in contrast, PD 123319 showed more than 10,000-fold selectivity in the opposite direction. The peptide agonist angiotensin III and [des-Phe 8 ]Ang II bound more avidly to this smaller population of sites (700 -fold and 40-fold, respectively). Ang II itself showed similar affinities for the two components (within one-half log unit). The AT 2 antagonist CGP 42112A was relatively weak (K h >1 fjM) at both sites. The subpopulation of specific binding sites with high affinity for losartan was termed the ATj A site, and the subpopulation with high affinity for PD 123319 was termed the ATi B site. The relative affinities (pIQo) of Ang II, losartan, PD 123319, and CGP 42112A at the AT 1B site are shown in Figure 1 (squares) .
Inhibition of Adenylyl Cyclase
The effects of the different antagonists on the inhibition by Ang II of forskolin-stimulated cyclic AMP production were analyzed in rat mesangial cell membranes. Ang II inhibited forskolin-stimulated adenylyl cyclase in a concentration-dependent fashion (IQo, 35 ±7 nM), and the maximal inhibition of adenylyl cyclase was 44±2% (Figure 2 ). Much higher concentrations of Ang II (100-fold) are required to inhibit adenylyl cyclase than to occupy either the AT 1A or AT 1B receptor subtypes (Figure 1 ). Losartan could antagonize completely the inhibition of adenylyl cyclase elicited by 0.1 /xM Ang II but with low potency relative to AT^ (IQo, 0.5±0.2 ^.M). PD 123319 also competed for Ang H-induced inhibition of adenylyl cyclase 
1.2±0.4 JAM)
. CGP 42112A was less potent 5.7±1.6 uM) (Figure 3) . Comparison of binding affinities at AT 1B receptor sites with antagonist potencies in the adenylyl cyclase assay show good agreement for losartan and CGP 42112A, whereas PD 123319 is less potent than expected from membrane binding assays ( Figure 1 ). Approximately 1,000-fold difference was noted between binding affinity and adenylyl cyclase regulation. The latter discrepancy may be explained by a partial agonist action of PD 123319 at AT 1B receptors. 17 These data further support the heterogeneity of renal angiotensin receptors.
Discussion
In the present study we demonstrate that specific '^I-fSar'JAng II binding to cultured rat mesangial cells corresponds to two subgroups of receptor sites, here proposed as AT 1A and AT 1B . AT 1A showed a higher affinity for losartan (nanomolar) and lower affinity for PD 123319 (micromolar). In contrast, AT 1B displayed a higher affinity (nanomolar) for PD 123319 and lower affinity for losartan (micromolar). GTPyS and pertussis toxin interfere with binding to both sites, suggesting that one or more G proteins may modulate receptor interactions. 11 Masking experiments suggested that GTP-yS was fourfold more potent in inhibiting the AT, A component of binding relative to the AT 1B component. When a G protein is involved in a signal transduction system, GTP is required for agonist-induced second messenger production. In our experiment, Ang IIinduced inhibition of Ang II on adenylyl cyclase required the presence of GTP (data not shown), consistent with observations of Crawford et al, 18 who used 7315c cells derived from rat anterior pituitary tumor. In mesangial cell membranes stimulated with GTP and forskolin, Ang II inhibited adenylyl cyclase activity by a maximum of 44% at 10 JAM. Similar results were reported by Bauer and colleagues 19 using rat liver membranes. Ang II-elicited adenylyl cyclase inhibition appeared to be mediated through an AT 1A -like receptor, because losartan but not PD 123177 blocks the effect of Ang II.
18
- 19 However, losartan is a relatively weak antagonist (IQo, approximately 1 uM) relative to its inhibitory action on vascular smooth muscle inositol phosphate metabolism and calcium mobilization (IQo, approximately 10 nM). 20 The subtype of Ang II receptor coupled to adenylyl cyclase inhibition in various cell types remains to be fully denned. Because a 100-fold higher concentration of Ang II is required to inhibit mesangial cell adenylyl cyclase than to occupy either the AT 1A or AT 1B receptor subtypes (Figure 1) , it would seem that more Ang II receptors must be occupied by an agonist for inhibition of adenylyl cyclase than for inositol trisphosphate-induced calcium mobilization. 17 A similar discrepancy was noted in the liver. 19 This differs from observations in 7315c cells, where the binding affinity to a single site and IQo values for adenylyl cyclase inhibitions agreed within one log unit. 18 Our results suggest that the proposed AT 1B subtype is coupled to effects typically associated with the AT] receptor. Ang II inhibited the activity of forskolinstimulated adenylyl cyclase, and losartan, PD 123319, and CGP 42112A all antagonized Ang II-induced inhibition of adenylyl cyclase. The AT 2 peptide antagonist CGP 42112A was the least potent. In recent studies in our laboratories, we have shown that PD 123319 is a potent antagonist (IQo, <1 nM) of the calcium response to Ang II in mesangial and renal epithelial cells, implying functional coupling of AT 1B receptors to signaling pathways regulating intracellular calcium. 17 However, PD 123319 also elicited agonist actions when administered alone, which may account for its reduced potency in functional assays relative to its binding affinity (1,000-fold difference). We cannot rule out the possibility that AT [A receptors also contribute to the adenylyl cyclase response. However, the low potency of losartan in the present study, relative to other studies, suggests that a renal subtype with low affinity for losartan as identified in binding assays may be primarily responsible for adenylyl cyclase inhibition. This novel subtype coupled to adenylyl cyclase inhibition may be the AT 1B or a previously unknown subtype.
Multiple subtypes of AT! have recently been cloned, and Northern blot analyses have revealed that the messenger RNA for AT,, is expressed in aortic vascular smooth muscle cells, lung, and ovary; the messenger RNA for a putative AT lb is expressed in adrenal, uterus, and anterior pituitary; and these two RNAs are expressed in liver, kidney, and spleen at similar levels. 21 -25 But this AT lb differs substantially from our AT 1B because it did not bind PD 123319 and is pharmacologically indistinguishable from the AT 1A subtype.
In the present study using rat mesangial cell membranes, we demonstrate clearly that there are two subtypes of AT[ receptor. AT 1A has higher affinity for losartan, whereas AT 1B has higher affinity for PD 123319. Two distinct receptors appear to be coupled to adenylyl cyclase through G|. One of these receptors appears to be an AT U subtype, whereas the functional role of ATIB in the kidney remains to be defined.
